Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

PubWeight™: 5.57‹?› | Rank: Top 1%

🔗 View Article (PMC 3278055)

Published in Chest on February 01, 2012

Authors

Anne Holbrook1, Sam Schulman, Daniel M Witt, Per Olav Vandvik, Jason Fish, Michael J Kovacs, Peter J Svensson, David L Veenstra, Mark Crowther, Gordon H Guyatt, American College of Chest Physicians

Author Affiliations

1: Division of Clinical Pharmacology and Therapeutics, Department of Medicine, McMaster University, Hamilton, ON, Canada. holbrook@mcmaster.ca

Articles citing this

(truncated to the top 100)

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 10.75

Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.82

Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.56

Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.85

Warfarin pharmacogenetics. Trends Cardiovasc Med (2014) 1.57

Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis. J Thromb Haemost (2013) 1.46

Are evidence standards different for genomic- vs. clinical-based precision medicine? - A quantitative analysis of individualized warfarin therapy. Clin Pharmacol Ther (2017) 1.39

Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed. Can Fam Physician (2012) 1.38

Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document". Blood Transfus (2013) 1.23

Pharmacogenetics in clinical practice: how far have we come and where are we going? Pharmacogenomics (2013) 1.15

Influence of the VKORC1 3730 G > A polymorphism on warfarin dose. Eur J Clin Pharmacol (2012) 1.07

Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J (2014) 1.05

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol (2013) 1.05

Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics. BMC Health Serv Res (2013) 0.98

Cancer-associated thrombosis: clinical presentation and survival. Cancer Manag Res (2013) 0.98

Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis (2016) 0.96

Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J (2015) 0.93

At-Home Versus In-Clinic INR Monitoring: A Cost-Utility Analysis from The Home INR Study (THINRS). J Gen Intern Med (2016) 0.92

The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin Genet (2014) 0.90

Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency. J Gen Intern Med (2015) 0.88

Potential of a Pharmacogenetic-Guided Algorithm to Predict Optimal Warfarin Dosing in a High-Risk Hispanic Patient: Role of a Novel NQO1*2 Polymorphism. J Investig Med High Impact Case Rep (2016) 0.87

Pharmacogenetic testing: Current Evidence of Clinical Utility. Ther Adv Drug Saf (2013) 0.87

Evaluation of education on the appropriate use of vitamin k in warfarin reversal in adult inpatients. Hosp Pharm (2013) 0.87

A pharmacogenetics service experience for pharmacy students, residents, and fellows. Am J Pharm Educ (2013) 0.86

Users' guide to the surgical literature: how to evaluate clinical practice guidelines. Can J Surg (2014) 0.85

Venous thromboembolism in cirrhosis: a review of the literature. Can J Gastroenterol (2012) 0.85

The role of prothrombin complex concentrates in reversal of target specific anticoagulants. Thromb J (2014) 0.85

Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study). Crit Care (2014) 0.84

Clinical use and the Italian demand for prothrombin complex concentrates. Blood Transfus (2013) 0.83

Comparison of warfarin therapy clinical outcomes following implementation of an automated mobile phone-based critical laboratory value text alert system. BMC Med Genomics (2014) 0.82

Respiratory review of 2013: pulmonary thromboembolism. Tuberc Respir Dis (Seoul) (2013) 0.82

Reversal of oral anticoagulation. Pharmacotherapy (2013) 0.82

Care transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safety. Ochsner J (2013) 0.82

Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag (2015) 0.81

Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal. Transfusion (2015) 0.81

A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal. Crit Care (2013) 0.81

Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials. PLoS One (2015) 0.81

Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. Am J Kidney Dis (2014) 0.80

Safety of a Four-factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials. Acad Emerg Med (2016) 0.80

Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.80

Interrupting anticoagulation in patients with nonvalvular atrial fibrillation. P T (2014) 0.80

Is home monitoring of international normalised ratio safer than clinic-based monitoring? Interact Cardiovasc Thorac Surg (2012) 0.79

Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE. Nat Rev Cardiol (2012) 0.79

Timing of discharge follow-up for acute pulmonary embolism: retrospective cohort study. West J Emerg Med (2015) 0.79

A survey of nursing home physicians to determine laboratory monitoring adverse drug event alert preferences. Appl Clin Inform (2014) 0.79

Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach. Curr Treat Options Cardiovasc Med (2013) 0.79

A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome Med (2016) 0.78

Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.78

Engaging with quality improvement in anticoagulation management. J Thromb Thrombolysis (2015) 0.78

Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin. Chest (2015) 0.78

Multidisciplinary model to implement pharmacogenomics at the point of care. Genet Med (2016) 0.78

Prediction of individual combined benefit and harm for patients with atrial fibrillation considering warfarin therapy: a study protocol. BMJ Open (2015) 0.77

Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.77

Withdrawal of Antithrombotic Agents and the Risk of Stroke. J Stroke Cerebrovasc Dis (2016) 0.77

Patients' and physicians' satisfaction with a pharmacist managed anticoagulation program in a family medicine clinic. BMC Res Notes (2015) 0.77

Comparison of international normalized ratio measurement between CoaguChek XS Plus and STA-R coagulation analyzers. Biomed Res Int (2012) 0.77

Warfarin dose requirements in a patient with the CYP2C9*14 allele. Pharmacogenomics (2014) 0.77

Initial thrombolysis treatment compared with anticoagulation for acute intermediate-risk pulmonary embolism: a meta-analysis. J Thorac Dis (2015) 0.77

Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation in real-world practice: a population-based cohort study protocol. BMJ Open (2016) 0.77

Antidotes to coumarins, isoniazid, methotrexate and thyroxine, toxins that work via metabolic processes. Br J Clin Pharmacol (2015) 0.77

Guidelines on vitamin D replacement in bariatric surgery: Identification and systematic appraisal. Metabolism (2016) 0.77

Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. Eur J Clin Pharmacol (2014) 0.76

Platelet dysfunction in thrombosis patients treated with vitamin K antagonists and recurrent bleeding. PLoS One (2013) 0.76

Global assays and the management of oral anticoagulation. Thromb J (2015) 0.76

Prothrombin complex concentrate. Hosp Pharm (2013) 0.75

New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty. World J Orthop (2014) 0.75

An unusual occurrence: a case of venous thromboembolism in pregnancy associated with heterotaxy syndrome. BMC Hematol (2015) 0.75

Management of venous thromboembolism: clinical guidance from the Anticoagulation Forum. J Thromb Thrombolysis (2016) 0.75

Warfarin-induced skin necrosis. Hosp Pharm (2014) 0.75

Recurrent venous thromboembolism in a patient with heterozygous factor v leiden mutation. Hosp Pharm (2014) 0.75

Use of onabotulinumtoxinA for overactive bladder with concomitant warfarin. Consult Pharm (2014) 0.75

Gastrointestinal bleeding and anticoagulant or antiplatelet drugs: systematic search for clinical practice guidelines. Medicine (Baltimore) (2015) 0.75

Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis. BMJ Open (2014) 0.75

Deep Vein Thrombosis of the Left Lower Limb in a 12 Year-Old Female Child with Ulcerative Colitis - Case Report. Pol J Radiol (2016) 0.75

Comparison of 3-Factor Prothrombin Complex Concentrate and Low-Dose Recombinant Factor VIIa for Warfarin Reversal. World J Emerg Surg (2014) 0.75

The clinical impact of different coagulometers on patient outcomes. Adv Ther (2014) 0.75

Warfarin: its highs and lows. Can Fam Physician (2013) 0.75

Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist. BMC Health Serv Res (2015) 0.75

Demonstration of anticoagulation patient self-testing feasibility at an Indian Health Service facility: A case series analysis. Pharm Pract (Granada) (2013) 0.75

Thrombosis - Besieged but Poorly Understood. Front Cardiovasc Med (2014) 0.75

The Role of Pharmacomechanical Endovascular Intervention for Iliofemoral Vein Thrombosis Compared to Conventional Anticoagulation Therapy. J Korean Med Sci (2017) 0.75

An evaluation of intravenous vitamin k for warfarin reversal: are guideline recommendations being followed? Hosp Pharm (2015) 0.75

Factors influencing warfarin response in hospitalized patients. Saudi Pharm J (2015) 0.75

Warfarin Re-initiation Gone Awry: A Case of Inadvertent Overdose Mandating Critical INR Management. Can J Hosp Pharm (2015) 0.75

Cardiovascular Pharmacogenomics-Implications for Patients With CKD. Adv Chronic Kidney Dis (2016) 0.75

Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting. Anesth Analg (2016) 0.75

Macroscopic hematuria in patients on anticoagulation therapy. Cent European J Urol (2015) 0.75

Prothrombin complex concentrates in warfarin anticoagulation reversal. Rev Bras Hematol Hemoter (2012) 0.75

Novel associations of VKORC1 variants with higher acenocoumarol requirements. PLoS One (2013) 0.75

Discrepancies between Patients' Preferences and Educational Programs on Oral Anticoagulant Therapy: A Survey in Community Pharmacies and Hospital Consultations. PLoS One (2016) 0.75

Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher? BMJ Case Rep (2015) 0.75

Significant Modules and Biological Processes between Active Components of Salvia miltiorrhiza Depside Salt and Aspirin. Evid Based Complement Alternat Med (2016) 0.75

Warfarin pharmacogenetics: does more accurate dosing benefit patients? Semin Thromb Hemost (2012) 0.75

Drug-related problems and potential contributing factors in the management of deep vein thrombosis. BMC Hematol (2016) 0.75

Prothrombin complex concentrate for warfarin-induced bleeding in a patient with a mechanical aortic valve. Interact Cardiovasc Thorac Surg (2013) 0.75

Spontaneous iliopsoas muscle haematoma as a complication of anticoagulation in acute cerebral venous thrombosis: to stop or not to stop (the anticoagulation)? BMJ Case Rep (2015) 0.75

Health system capacity and infrastructure for adopting innovations to care for patients with venous thromboembolic disease. Open Med (2014) 0.75

Severe Extra-Cerebral Anticoagulant-Related Bleeding in Intensive Care Unit: A Retrospective Study From 2000 to 2013. Medicine (Baltimore) (2015) 0.75

Articles cited by this

(truncated to the top 100)

Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost (2006) 16.11

Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA (1994) 13.60

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 10.75

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65

Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55

Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med (2003) 8.33

The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med (1995) 8.08

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94

Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA (1994) 7.85

Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med (1999) 7.74

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12

A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med (2003) 6.57

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation (2007) 5.99

Systematic overview of warfarin and its drug and food interactions. Arch Intern Med (2005) 5.86

Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA (2006) 5.69

Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med (2009) 5.48

Effect of home testing of international normalized ratio on clinical events. N Engl J Med (2010) 5.36

Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med (1995) 5.16

Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet (2006) 5.11

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.82

Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol (2010) 4.78

Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet (2011) 4.78

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 4.52

Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med (1997) 4.47

Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.30

Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med (2010) 4.01

Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94

Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med (1998) 3.91

An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med (1996) 3.86

Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med (1992) 3.74

Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ (2003) 3.73

Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med (1989) 3.65

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther (2007) 3.60

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 3.59

Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.56

Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest (2006) 3.54

Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med (2011) 3.53

Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet (2000) 3.50

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost (2005) 3.47

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med (2009) 3.44

Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med (1998) 3.44

The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med (1993) 3.43

Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med (1994) 3.33

Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.14

Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet (1996) 3.03

Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest (2006) 2.79

Prospective comparative study of computer programs used for management of warfarin. J Clin Pathol (1993) 2.73

Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med (1990) 2.63

Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost (2008) 2.60

Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 2.54

Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med (2007) 2.50

Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med (2006) 2.40

Oral anticoagulation management in primary care with the use of computerized decision support and near-patient testing: a randomized, controlled trial. Arch Intern Med (2000) 2.36

Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol (2000) 2.35

Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev (2010) 2.32

Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood (2006) 2.27

A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics (2010) 2.19

Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med (1992) 2.16

A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators. Am Heart J (1999) 2.09

Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess (2007) 2.06

Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost (2008) 2.05

A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res (2005) 2.05

Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ (2008) 2.02

Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ (2007) 2.02

Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med (1999) 2.00

Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med (2011) 1.98

Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med (2002) 1.95

Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med (2005) 1.91

Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions. Pharmacotherapy (2004) 1.91

Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest (2005) 1.90

Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents: a population-based study. Arch Intern Med (2010) 1.87

Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood (2009) 1.84

Evaluation of computerized decision support for oral anticoagulation management based in primary care. Br J Gen Pract (1996) 1.83

A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum (2007) 1.82

Guidelines on oral anticoagulation: third edition. Br J Haematol (1998) 1.80

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet (1992) 1.73

A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med (1999) 1.72

The effectiveness of warfarin dosing from a nomogram compared with house staff dosing. J Arthroplasty (2007) 1.67

Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb Haemost (1993) 1.65

Guideline-based consultation to prevent anticoagulant-related bleeding. A randomized, controlled trial in a teaching hospital. Ann Intern Med (1992) 1.65

Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions. J Manag Care Pharm (2006) 1.63

Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet (1985) 1.60

The Belgian Improvement Study on Oral Anticoagulation Therapy: a randomized clinical trial. Eur Heart J (2005) 1.58

Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med (2005) 1.56

Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med (2000) 1.55

Evaluation of a decision support system for initiation and control of oral anticoagulation in a randomised trial. BMJ (1997) 1.51

Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke (1992) 1.48

Bleeding Risk Index in an anticoagulation clinic. Assessment by indication and implications for care. J Gen Intern Med (2005) 1.48

Reexamining the recommended follow-up interval after obtaining an in-range international normalized ratio value: results from the Veterans Affairs study to improve anticoagulation. Chest (2011) 1.47

Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet (1998) 1.47

Validation of a weight-based nomogram for the use of intravenous heparin in transient ischemic attack or stroke. Stroke (2002) 1.46

Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics (2009) 1.41

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes (2009) 1.38

Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med (1998) 1.38

Relationship between patients' warfarin knowledge and anticoagulation control. Ann Pharmacother (2003) 1.37

Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med (2004) 1.36

Outcome analysis of a pharmacist-managed anticoagulation service. Pharmacotherapy (1996) 1.35

The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol (2004) 1.31

Articles by these authors

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med (2008) 31.57

Grading quality of evidence and strength of recommendations. BMJ (2004) 26.08

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation (2005) 18.90

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17

Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA (2006) 11.71

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00

Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 10.75

GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol (2011) 10.02

Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med (2001) 8.95

ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med (2003) 8.83

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77

Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55

Randomized trials stopped early for benefit: a systematic review. JAMA (2005) 8.43

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol (2009) 7.94

Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res (2004) 7.20

Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med (2003) 7.15

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12

A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med (2003) 6.57

High-frequency oscillation in early acute respiratory distress syndrome. N Engl J Med (2013) 6.56

Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med (2011) 6.56

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood (2011) 6.50

Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA (2008) 6.39

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.99

Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA (2010) 5.90

Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88

Systematic overview of warfarin and its drug and food interactions. Arch Intern Med (2005) 5.86

Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA (2007) 5.69

Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med (2012) 5.67

Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers: a systematic review and meta-analysis. JAMA (2002) 5.57

Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med (2009) 5.48

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.29

A Trial of Wound Irrigation in the Initial Management of Open Fracture Wounds. N Engl J Med (2015) 5.28

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26

Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ (2008) 5.16

Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.02

A systematic review and meta-analysis of studies comparing mortality rates of private for-profit and private not-for-profit hospitals. CMAJ (2002) 4.84

Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.82

Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med (2011) 4.59

VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.50

Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 4.49

Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48

Internet versus mailed questionnaires: a randomized comparison (2). J Med Internet Res (2004) 4.45

The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med (2009) 4.41

Need for expertise based randomised controlled trials. BMJ (2005) 4.34

Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 4.30

Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 4.29

Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest (2005) 4.29

An observational study of orthopaedic abstracts and subsequent full-text publications. J Bone Joint Surg Am (2002) 4.25

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01

Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med (2014) 3.96

Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.87

Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 3.86

Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.81

Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis. JAMA (2009) 3.81

Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine. Chest (2001) 3.77

A new 'mechanistic-practical" framework for designing and interpreting randomized trials. J Clin Epidemiol (2008) 3.75

The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74

Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ (2003) 3.73

The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklist. Control Clin Trials (2002) 3.62

Physicians' and patients' choices in evidence based practice. BMJ (2002) 3.57

Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.56

Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest (2003) 3.55

Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ (2010) 3.54

The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med (2010) 3.47

Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 3.46

Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev (2011) 3.44

Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med (2013) 3.40

Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ (2009) 3.39

Barriers to full-text publication following presentation of abstracts at annual orthopaedic meetings. J Bone Joint Surg Am (2003) 3.36

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.36

Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest (2007) 3.36

Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol (2002) 3.36

Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.31

Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ (2011) 3.28

Validity of composite end points in clinical trials. BMJ (2005) 3.26

Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet (2006) 3.25

Quality of care in for-profit and not-for-profit nursing homes: systematic review and meta-analysis. BMJ (2009) 3.22

Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.14

Internal fixation compared with arthroplasty for displaced fractures of the femoral neck. A meta-analysis. J Bone Joint Surg Am (2003) 3.14

ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians. J Am Soc Echocardiogr (2011) 3.13

Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis. CMAJ (2010) 3.13

Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation (2009) 3.10

Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.08